Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

Exclusion Criteria

• •1. Known cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).
• •2. Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
• •3. Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC.
• •4. Any HCC treatment prior to enrollment/blood sample collection (e.g., surgery, ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other treatment indicated for HCC).
• •5. IV contrast (e.g. CT and MRI) within 1 day \[or 24 hours\] of blood collection.
• •6. Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.
• •7. Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.
• •8. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.